Most current drug therapy development is based on research of genes that were discovered in 1987 and are responsible for early onset Alzheimer's disease, which accounts for only 5-10% of the total Alzheimer's population.
 
A+ | A- | Reset
Board of Directors
Dr. John S. Lazo

Photo of Dr. John S. LazoJohn S. Lazo, Ph.D. is a professor and chair in the department of pharmacology at the University of Pittsburgh School of Medicine: Co-director of the molecular therapeutics/drug discovery program at the University of Pittsburgh Cancer Institute.

more>
 
Henry F. McCance

Photo of Henry F. McCanceFounding Board Member
Henry F. McCance is Chairman of the Board and President of Greylock Management Corporation and General Partner in a variety of Greylock private, limited partnerships for equity investments.

more>
 
Jacqueline C. Morby

Photo of Jacqueline C. MorbyFounding Board Member
Jacqueline C. Morby was a Managing Director of TA Associates from 1982 to 2002 and served on the firm's Executive Committee from 1988 to 2001. 

more>
 
Jeffrey L. Morby

Photo of Jeffrey L. MorbyChairman of the Cure Alzheimer's Fund Board of Directors, Founding Board Member
In addition to the Cure Alzheimer's Fund, Mr. Morby is also Chairman of the Morby Family Charitable Foundation, and director of the Andrew and Velda Morby Educational Foundation.

more>
 
Phyllis Rappaport

Photo of Phyllis RappaportFounding Board Member
Phyllis Rappaport chairs her family's philanthropy, the Jerome Lyle Rappaport Charitable Foundation and is a director of New Boston Fund, Inc., where she oversees strategy planning, human resource planning and development, and organizational performance.

more>
 
Dr. William E. Trueheart

Dr. William E. Trueheart is President and Chief Executive Officer of The Pittsburgh Foundation.

more>
 
Timothy W. Armour

Photo of Timothy W. ArmourTim Armour is President and Chief Executive Officer of the Cure Alzheimer's Fund.

more>